Compare Lockheed Martin Corporation (LMT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Sana Biotechnology Inc — how do they compare? Lockheed Martin Corporation trades at $608.87 (market cap $137.96B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Lockheed Martin Corporation is far larger — about 122.1× Sana Biotechnology Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| LMT | SANA | |
|---|---|---|
Market Cap | $137.96B | $1.13B |
Sector | Industrials | Health |
52-Week High | $676.70 | $5.92 |
52-Week Low | $431.56 | $2.68 |
Enterprise Value | $154.71B | $1.05B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $606.71, up 0.59% on the day, near its consensus price target of $608. The stock shows bullish technical momentum with strong moving average signals and is supported by a record $230.4 billion backlog as of Q2 2026 (Seeking Alpha, August 4, 2026). Recent earnings beat expectations in Q2 2026 with EPS of $7.94 versus $7.22 estimated, though Q4 2025 and Q1 2026 results missed. The company maintains robust cash flow, with 2025 operating cash flow at $8.56 billion, and benefits from major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, August 11, 2026).
Outlook is positive due to strong defense spending trends and execution, but risks include earnings volatility and debt levels. The stock offers steady dividends and growth potential, with analyst consensus leaning bullish. Key risks involve reliance on government contracts and macroeconomic pressures on defense budgets.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
